Many components of mitogenic signaling pathways in normal and neoplastic cells have
been identified, including the large family of protein kinases, which function as components …

The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Kinases have emerged as one of the most intensively pursued targets in current
pharmacological research, especially for cancer, due to their critical roles in cellular …

We have previously examined the specificities of 28 commercially available compounds,
reported to be relatively selective inhibitors of particular serine/threonine-specific protein …

Background: Protein kinases are essential enzymes propagating cellular signal transduction
processes and consequently have emerged as central targets for drug discovery against a …

Kinase inhibition is a major area for therapeutic intervention against a variety of diseases
including cancer, inflammatory disorders and diabetes. While this mode of action remains …

Cancer is the second leading cause of death in the western world. Despite advances in
diagnosis and treatment, overall survival of patients remains poor. Scientific advances in …

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the
United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the …

The most essential kinases involved in cell membrane receptor activation, signal
transduction and cell cycle control or programmed cell death and their interconections are …

Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging
from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular …